CJC (no DAC)

RUO Disclaimer: All QRM products are strictly for in vitro laboratory and research use only by qualified researchers in appropriate facilities. Nothing here implies, suggests, or recommends any diagnostic, therapeutic, or clinical application or use in humans or animals.

The Research Lab

Explore the Article

An interactive deep-dive, visual science journalism you can explore.

Discover Now →

CJC (no DAC)

4.7 (18 reviews)

A growth hormone releasing hormone (GHRH) analog studied for its role in amplifying growth hormone pulse research models. Most frequently co-researched alongside Ipamorelin for complementary receptor pathway studies.

$60.00

🔥 16 sold in the last 24 hours

Order in for same-day shipping

Select a size to see availability

🔥 16 sold in the last 24 hours

Order in for same-day shipping

Select a size to see availability

A growth hormone releasing hormone (GHRH) analog studied for its role in amplifying growth hormone pulse research models. Most frequently co-researched alongside Ipamorelin for complementary receptor pathway studies.

About CJC (no DAC)

CJC-1295 no DAC is built on the same foundational sequence as native GHRH(1-29), the biologically active portion of growth hormone-releasing hormone, with several amino acid substitutions introduced to improve the peptide’s stability and resistance to enzymatic breakdown at the cellular level. These modifications extend its functional half-life relative to unmodified GHRH without reaching the prolonged duration associated with the DAC version, preserving a more physiologically relevant release pattern for controlled research purposes.

Growth hormone is not secreted continuously in research models. It is released in discrete pulses in response to specific receptor-mediated cues, and this pulsatile pattern is studied as important for downstream growth hormone signaling effects. Researchers have studied CJC-1295 no DAC specifically because its shorter duration of action is more compatible with this natural release dynamic than longer-acting GHRH analogues. For investigators studying growth hormone biology under conditions that approximate endogenous receptor signaling patterns, this distinction is a meaningful part of the compound’s research utility.

The most studied application of CJC-1295 no DAC involves its combination with Ipamorelin. The two compounds act on different but complementary receptor systems: CJC-1295 no DAC stimulates GHRH receptors to amplify the growth hormone-releasing signal, while Ipamorelin acts on ghrelin receptors to trigger pituitary release. Research has examined whether this dual-receptor approach produces a more complete and robust growth hormone response than either compound alone in controlled research settings, and this combination has become one of the most referenced pairings in growth hormone secretagogue research.

GHRH Receptor Binding and Growth Hormone Stimulation: CJC-1295 no DAC has been studied for its binding to GHRH receptors on pituitary somatotroph cells, an interaction that amplifies the signal for growth hormone synthesis and release in vitro. Research has examined how the peptide’s modified amino acid sequence extends its receptor binding activity relative to native GHRH while preserving the pulsatile release dynamic that characterizes endogenous growth hormone secretion in research models.
Growth Hormone Pulse Amplitude Modulation: Studies have investigated CJC-1295 no DAC’s effects on growth hormone pulse amplitude, with research examining whether GHRH receptor stimulation increases the quantity of growth hormone released per pulse without significantly altering pulse frequency. This distinction has been studied as relevant to the physiological authenticity of the growth hormone response in controlled research settings.
IGF-1 Downstream Signaling: Research has examined CJC-1295 no DAC’s downstream effects on IGF-1, the primary tissue-level mediator of growth hormone pathway activity. Studies have investigated the relationship between GHRH receptor stimulation, growth hormone output, and subsequent IGF-1 elevation as a readout of the compound’s biological activity across treated research models.
Combined Receptor Pathway Activity with Ipamorelin: CJC-1295 no DAC has been studied in combination with Ipamorelin, with research examining the effects of simultaneous GHRH receptor and ghrelin receptor stimulation on growth hormone output in vitro. Investigators have studied whether combining these two receptor pathways produces a more robust growth hormone response than activating either receptor system independently in controlled research environments.
Body Composition and Metabolic Signaling: Studies have examined the effects of CJC-1295 no DAC-driven growth hormone stimulation on body composition markers, tissue repair signaling, and metabolic indicators in preclinical research models. Research has investigated how sustained but physiologically patterned growth hormone elevation influences these signaling outcomes at the cellular level.

Pulsatile Growth Hormone Stimulation

CJC-1295 no DAC occupies a specific and deliberate position in growth hormone research: it is designed to stimulate growth hormone release in a pattern that preserves the pulsatile dynamics of endogenous GHRH receptor activity rather than producing sustained elevation. Research has examined whether this physiologically patterned release produces downstream signaling effects distinct from those associated with longer-acting GHRH analogues in controlled research settings.

Combined Receptor Research with Ipamorelin

The most referenced application of CJC-1295 no DAC in the research literature is its combination with Ipamorelin, a pairing that engages both GHRH and ghrelin receptor pathways simultaneously. Studies have examined the additive and potentially complementary effects of dual-receptor stimulation on growth hormone output, with this combination establishing itself as a standard reference point in growth hormone secretagogue research.

IGF-1 and Downstream Signaling

Research has examined CJC-1295 no DAC's effects on IGF-1 as a primary biological readout of growth hormone axis activity in treated research models. Studies have investigated the relationship between the magnitude of IGF-1 response and body composition, tissue repair, and metabolic signaling markers observed across CJC-1295 no DAC research contexts in controlled research settings.

Composition and Tissue Repair Signaling

Studies have investigated the effects of CJC-1295 no DAC-driven growth hormone stimulation on body composition and tissue repair signaling markers in preclinical research models. Research has examined lean mass and fat metabolism pathway activity in growth hormone-deficient research models, alongside investigations into connective tissue, muscle, and bone repair signaling in contexts where growth hormone pathway activity is a key research variable.

Product Specifications

Reference

Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 91(12), 4792–4797.
Alba, M., Fintini, D., Sagazio, A., et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology: Endocrinology and Metabolism, 291(6), E1290–E1294.
Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research, 19(6), 471–477.